Paul D. Griffiths
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paul D. Griffiths has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Mike Sharland
Antibiotic Policy Group, School of Health and Medical Sciences, City St. George's University of London, London, United Kingdom
3 shared publications - Suzanne Luck
University College London, Division of Infection and Immunity, Royal Free Hospital, Rowland Hill Street, London NW3 2PF, UK
2 shared publications - Andrea Britta Maier
NUS Academy for Healthy Longevity, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore
1 shared publication Andrew Davenport
Centre for Nephrology, UCL Medical School, London
1 shared publicationAndrew K Burroughs
Sheila Sherlock Liver Centre and University Department of Surgery, Royal Free NHS Trust, UCL Medical School, London
1 shared publication- Anis Larbi
Biology of Aging Program and Immunomonitoring Platform, Singapore Immunology Network (SIgN), Agency for Science Technology and Research (A*STAR), Immunos Building, Biopolis, Singapore 138648, Singapore
1 shared publication
Latest Publications
- 1 June 2013
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 32 (6) , 682-683
The Novel Antiviral Pipeline to Treat Severe Neonatal Viral Infections
- 1 June 2013
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 32 (6) , 682-683
The Novel Antiviral Pipeline to Treat Severe Neonatal Viral Infections
- Open Access
- 17 January 2013
- Published by Springer Nature
Determining a Viral Load Threshold for Pre-emptive Therapy for Cytomegalovirus Infection in Transplant Patients Using Real Time PCR Monitoring.
- 17 January 2013
- Published by Springer Nature
Open AccessDetermining a Viral Load Threshold for Pre-emptive Therapy for Cytomegalovirus Infection in Transplant Patients Using Real Time PCR Monitoring.
- 27 April 2011
- Published by Wiley in Reviews in Medical Virology
- Vol. 21 (3) , 137-138
HCMV gets a Sat-Nav too
- 27 April 2011
- Published by Wiley in Reviews in Medical Virology
- Vol. 21 (3) , 137-138
HCMV gets a Sat-Nav too
- Top Cited PapersOpen Access
- 1 April 2011
- Published by Elsevier in The Lancet
- Vol. 377 (9773) , 1256-1263
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
- 1 April 2011
- Published by Elsevier in The Lancet
- Vol. 377 (9773) , 1256-1263
Top Cited PapersOpen AccessCytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
- Open Access
- 7 September 2010
- Published by Springer Nature in Immunity & Ageing
- Vol. 7 (1) , 1-5
Immunosenescence and Cytomegalovirus: where do we stand after a decade?
- 7 September 2010
- Published by Springer Nature in Immunity & Ageing
- Vol. 7 (1) , 1-5
Open AccessImmunosenescence and Cytomegalovirus: where do we stand after a decade?
- 3 September 2010
- Published by Springer Nature
- Vol. 697, 243-260
Antiviral Therapy of CMV Disease in Children
Cytomegalovirus (CMV) remains an important cause of morbidity and mortality in infants and children. The main burden of disease occurs in congenital infection, postnatal infection in premature infants and in older immunocompromised children (now predominantly following transplantation) in developed countries. In lower income countries, CMV is a major co-pathogen in human immunodeficiency virus [HIV]-infected infants. Antiviral treatment options remain very limited. The guanosine analogue ganciclovir (GCV) was first used in children over 20 years ago, but the optimal dose, duration and route of administration remain poorly evidence based. In particular there are very limited data in premature infants and older children. Direct comparison studies between the intravenous ganciclovir and the oral valyl-ester valganciclovir (VGCV) have not been performed. CMV disease is important, but not very common and there remains a need to identify useful surrogate markers of successful antiviral therapy to facilitate clinical trials. Cidofovir and foscarnet have very significant toxicity. No other anti-CMV agent has successfully completed phase III studies. There remain few other antiviral agents effective against CMV on the horizon. This chapter reviews the current clinical spectrum of CMV disease in childhood and the evidence base for both GCV and VGCV use in clinical practice. It also discusses the antiviral studies currently being performed and those that need to be performed.
- 3 September 2010
- Published by Springer Nature
- Vol. 697, 243-260
Antiviral Therapy of CMV Disease in Children
Cytomegalovirus (CMV) remains an important cause of morbidity and mortality in infants and children. The main burden of disease occurs in congenital infection, postnatal infection in premature infants and in older immunocompromised children (now predominantly following transplantation) in developed countries. In lower income countries, CMV is a major co-pathogen in human immunodeficiency virus [HIV]-infected infants. Antiviral treatment options remain very limited. The guanosine analogue ganciclovir (GCV) was first used in children over 20 years ago, but the optimal dose, duration and route of administration remain poorly evidence based. In particular there are very limited data in premature infants and older children. Direct comparison studies between the intravenous ganciclovir and the oral valyl-ester valganciclovir (VGCV) have not been performed. CMV disease is important, but not very common and there remains a need to identify useful surrogate markers of successful antiviral therapy to facilitate clinical trials. Cidofovir and foscarnet have very significant toxicity. No other anti-CMV agent has successfully completed phase III studies. There remain few other antiviral agents effective against CMV on the horizon. This chapter reviews the current clinical spectrum of CMV disease in childhood and the evidence base for both GCV and VGCV use in clinical practice. It also discusses the antiviral studies currently being performed and those that need to be performed.
- 1 May 2010
- Published by Elsevier in Journal of Clinical Virology
- Vol. 48, S2-S7
Advances in the understanding of the pathogenesis and epidemiology of herpes zoster
- 1 May 2010
- Published by Elsevier in Journal of Clinical Virology
- Vol. 48, S2-S7
Advances in the understanding of the pathogenesis and epidemiology of herpes zoster
- 1 December 2009
- Published by Elsevier in Journal of Clinical Virology
- Vol. 46, S64-S67
CMV vaccine trial endpoints
- 1 December 2009
- Published by Elsevier in Journal of Clinical Virology
- Vol. 46, S64-S67
CMV vaccine trial endpoints
- 30 September 2009
- Published by Elsevier in Journal of Clinical Virology
- Vol. 46 (1) , 3-8
A perspective on antiviral resistance
- 30 September 2009
- Published by Elsevier in Journal of Clinical Virology
- Vol. 46 (1) , 3-8
A perspective on antiviral resistance
- 1 October 2008
- Vol. 15 (1) , 4-12
Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007.
An international workshop reviewed the evidence base for deploying antiviral drugs to prevent cytomegalovirus (CMV) end-organ diseases (EOD) as well as the indirect effects of CMV in transplant recipients. Published studies demonstrate that both prophylaxis and pre-emptive therapy can be effective strategies for preventing EOD. However, the optimal drug, dosage and duration of treatment have not been defined for either prophylaxis or pre-emptive therapy and vary by transplant population. Each of these strategies presents practical challenges, including ensuring compliance with the planned management protocol. Furthermore, there is no evidence that either strategy is superior to the other. Non-randomized clinical trials suggest that late-onset disease and antiviral resistance are more problematic with prophylaxis than pre-emptive therapy, while prophylaxis more clearly controls some of the indirect effects of CMV than does pre-emptive therapy. Because of the medical importance of these indirect effects, especially graft rejection, future studies should be powered to directly address their control. Because pre-emptive therapy for CMV disease is used widely in clinical practice, the ability of newer drugs administered prophylactically to reduce the need for pre-emptive therapy is an appropriate primary endpoint for the conduct of randomized controlled trials. International agreement is required on the standard comparator drug(s) against which new drugs should be compared. For debate, we suggest that baseline pre-emptive therapy with oral valganciclovir should be the comparator for new drug evaluation because it is widely used in clinical practice in many groups of transplant patients.
- 1 October 2008
- Vol. 15 (1) , 4-12
Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007.
An international workshop reviewed the evidence base for deploying antiviral drugs to prevent cytomegalovirus (CMV) end-organ diseases (EOD) as well as the indirect effects of CMV in transplant recipients. Published studies demonstrate that both prophylaxis and pre-emptive therapy can be effective strategies for preventing EOD. However, the optimal drug, dosage and duration of treatment have not been defined for either prophylaxis or pre-emptive therapy and vary by transplant population. Each of these strategies presents practical challenges, including ensuring compliance with the planned management protocol. Furthermore, there is no evidence that either strategy is superior to the other. Non-randomized clinical trials suggest that late-onset disease and antiviral resistance are more problematic with prophylaxis than pre-emptive therapy, while prophylaxis more clearly controls some of the indirect effects of CMV than does pre-emptive therapy. Because of the medical importance of these indirect effects, especially graft rejection, future studies should be powered to directly address their control. Because pre-emptive therapy for CMV disease is used widely in clinical practice, the ability of newer drugs administered prophylactically to reduce the need for pre-emptive therapy is an appropriate primary endpoint for the conduct of randomized controlled trials. International agreement is required on the standard comparator drug(s) against which new drugs should be compared. For debate, we suggest that baseline pre-emptive therapy with oral valganciclovir should be the comparator for new drug evaluation because it is widely used in clinical practice in many groups of transplant patients.